NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--On the upcoming science conference call hosted by Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, excerpts from the presentation given on December 1, 2010 at the American Association of Cancer Research highlighting previously undescribed capabilities of Advaxis’ platform immunotherapy will be discussed by the Company’s science team. Insight into the Company’s clinical trial program will be addressed by Advaxis’ new VP of Clinical Operations, Dr. Robert Petit.
